Methods and Compositions for the Treatment of Immune Disorders
AssigneeThe University of North Carolina at Chapel Hill
InventorsJenny P.-Y. Ting, Haitao Wen
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of North Carolina at Chapel Hill
InventorsJenny P.-Y. Ting, Haitao Wen
Estimating the term…
The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins.
A method of treating an immune-related and/or inflammatory disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, whereby the plexin-A4 activity in said subject is reduced, thereby treating the immune-related disorder and/or inflammatory disorder.
A method of reducing cytokine production in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, thereby reducing the cytokine production the subject.
(canceled)
A method of treating an immune-related and/or inflammatory disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, whereby the Sema3A activity in said subject is reduced, thereby treating the immune-related disorder and/or inflammatory disorder.
A method of reducing cytokine production in a subject, comprising administering to the subject an effective amount of an inhibitor of Sema3A activity, thereby reducing the cytokine production the subject.
(canceled)
Dependencies are inferred from the claim text.